ID   NCI-H69/CPR
AC   CVCL_2137
SY   H69/CPR
DR   ECACC; 96042328
DR   Wikidata; Q54908104
RX   PubMed=1327513;
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325dellGGCAACCGT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line).
CC   Derived from metastatic site: Pleural effusion.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1579 ! NCI-H69
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 17
//
RX   PubMed=1327513;
RA   Twentyman P.R., Wright K.A., Mistry P., Kelland L.R., Murrer B.A.;
RT   "Sensitivity to novel platinum compounds of panels of human lung
RT   cancer cell lines with acquired and inherent resistance to
RT   cisplatin.";
RL   Cancer Res. 52:5674-5680(1992).
//